Differential impact of hepatic deficiency and total body inhibition of MTP on cholesterol metabolism and RCT in mice

Journal of Lipid Research

Volumn 55, Issue 5, 2014, Pages 816-825

  Dikkers, Arne ^a   Annema, Wijtske ^a,b   De Boer, Jan Freark ^a   Iqbal, Jahangir ^c   Hussain, Mahmood ^c   Tietge, Uwe J F ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Bile; High density lipoprotein; Lipoprotein metabolism; Liver metabolism; Microsomal triglyceride transfer protein; Reverse cholesterol transport; Transintestinal cholesterol excretion; Very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN B; BILE ACID; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; TRIACYLGLYCEROL; 9-(4-(2,5-DIMETHYL-4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1H-BENZIMIDAZOL-1-YL)BUTYL)-N-(2,2,2-TRIFLUOROETHYL)-9H-FLUORENE-9-CARBOXAMIDE; BENZIMIDAZOLE DERIVATIVE; CARRIER PROTEIN; CHOLESTEROL; FLUORENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; INTESTINE ABSORPTION; LIPID LIVER LEVEL; LIVER CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE CHOLESTEROL TRANSPORT; STEROL EXCRETION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; BIOSYNTHESIS; BLOOD; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; FECES; GENE INACTIVATION; GENETICS; HEPATOBILIARY SYSTEM; INTESTINE; LIVER; METABOLISM; SECRETION (PROCESS); TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; APOLIPOPROTEINS B; BENZIMIDAZOLES; BILIARY TRACT; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CHOLESTEROL; FECES; FLUORENES; GENE KNOCKOUT TECHNIQUES; HEPATOCYTES; INTESTINAL ABSORPTION; INTESTINES; LIVER; MACROPHAGES; MICE; ORGAN SPECIFICITY; TRIGLYCERIDES;

EID: 84899520245     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M042986     Document Type: Article

References (46)

1. Di Angelantonio, E., P. Gao, L. Pennells, S. Kaptoge, M. Caslake, A. Thompson, A. S. Butterworth, N. Sarwar, D. Wormser, D. Saleheen, et al. 2012. Lipid-related markers and cardiovascular disease prediction. JAMA. 307 : 2499-2506.
2. Robinson, J. G., S. Wang, and T. A. Jacobson. 2012. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am. J. Cardiol. 110 : 1468-1476.
3. Wetterau, J. R., M. C. Lin, and H. Jamil. 1997. Microsomal triglyceride transfer protein. Biochim. Biophys. Acta. 1345 : 136-150.
4. Berriot-Varoqueaux, N., L. P. Aggerbeck, M. Samson-Bouma, and J. R. Wetterau. 2000. The role of the microsomal triglyceride transfer protein in abetalipoproteinemia. Annu. Rev. Nutr. 20 : 663-697.
5. Hussain, M. M., P. Rava, M. Walsh, M. Rana, and J. Iqbal. 2012. Multiple functions of microsomal triglyceride transfer protein. Nutr. Metab. (Lond). 9 : 14.
6. Chang, B. H., W. Liao, L. Li, M. Nakamuta, D. Mack, and L. Chan. 1999. Liver-specific inactivation of the abetalipoproteinemia gene completely abrogates very low density lipoprotein/low density lipoprotein production in a viable conditional knockout mouse. J. Biol. Chem. 274 : 6051-6055.
7. Raabe, M., M. M. Veniant, M. A. Sullivan, C. H. Zlot, J. Bjorkegren, L. B. Nielsen, J. S. Wong, R. L. Hamilton, and S. G. Young. 1999. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J. Clin. Invest. 103 : 1287-1298.
8. Raabe, M., L. M. Flynn, C. H. Zlot, J. S. Wong, M. M. Veniant, R. L. Hamilton, and S. G. Young. 1998. Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc. Natl. Acad. Sci. USA. 95 : 8686-8691.
9. Josekutty, J., J. Iqbal, T. Iwawaki, K. Kohno, and M. M. Hussain. 2013. Microsomal triglyceride transfer protein inhibition induces endoplasmic reticulum stress and increases gene transcription via Ire 1α/cJun to enhance plasma ALT/AST. J. Biol. Chem. 288 : 14372-14383.
10. Gregg, R. E., and J. R. Wetterau. 1994. The molecular basis of abetalipoproteinemia. Curr. Opin. Lipidol. 5 : 81-86.
11. Tietge, U. J., A. Bakillah, C. Maugeais, K. Tsukamoto, M. Hussain, and D. J. Rader. 1999. Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J. Lipid Res. 40 : 2134-2139.
12. Liao, W., K. Kobayashi, and L. Chan. 1999. Adenovirus-mediated overexpression of microsomal triglyceride transfer protein (MTP): mechanistic studies on the role of MTP in apolipoprotein B-100 biogenesis. Biochemistry. 38 : 10215.
13. Iqbal, J., J. S. Parks, and M. M. Hussain. 2013. Lipid absorption defects in intestine-specific microsomal triglyceride transfer protein and ATP-binding cassette transporter A1-deficient mice. J. Biol. Chem. 288 : 30432-30444.
14. Xie, Y., E. P. Newberry, S. G. Young, S. Robine, R. L. Hamilton, J. S. Wong, J. Luo, S. Kennedy, and N. O. Davidson. 2006. Compensatory increase in hepatic lipogenesis in mice with conditional intestinespecific Mttp deficiency. J. Biol. Chem. 281 : 4075-4086.
15. Cuchel, M., E. A. Meagher, H. du Toit Theron, D. J. Blom, A. D. Marais, R. A. Hegele, M. R. Averna, C. R. Sirtori, P. K. Shah, D. Gaudet, et al. 2013. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 381 : 40-46.
16. Cuchel, M., L. T. Bloedon, P. O. Szapary, D. M. Kolansky, M. L. Wolfe, A. Sarkis, J. S. Millar, K. Ikewaki, E. S. Siegelman, R. E. Gregg, et al. 2007. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356 : 148-156.
17. Lee, R. G., W. Fu, M. J. Graham, A. E. Mullick, D. Sipe, D. Gattis, T. A. Bell, S. Booten, and R. M. Crooke. 2013. Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein. J. Lipid Res. 54 : 602-614.
18. Linsel-Nitschke, P., and A. R. Tall. 2005. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. 4 : 193-205.
19. Wang, X., and D. J. Rader. 2007. Molecular regulation of macrophage reverse cholesterol transport. Curr. Opin. Cardiol. 22 : 368-372.
20. Annema, W., and U. J. Tietge. 2012. Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. Nutr. Metab. (Lond). 9 : 25.
21. Dikkers, A., and U. J. Tietge. 2010. Biliary cholesterol secretion: more than a simple ABC. World J. Gastroenterol. 16 : 5936-5945.
22. Annema, W., A. Dikkers, J. Freark de Boer, T. Gautier, P. C. Rensen, D. J. Rader, and U. J. Tietge. 2012. ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma. J. Lipid Res. 53 : 929-940.
23. Yamamoto, S., H. Tanigawa, X. Li, Y. Komaru, J. T. Billheimer, and D. J. Rader. 2011. Pharmacologic suppression of hepatic ATPbinding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport. Circulation. 124 : 1382-1390.
24. Wiersma, H., N. Nijstad, T. Gautier, J. Iqbal, F. Kuipers, M. M. Hussain, and U. J. Tietge. 2010. Scavenger receptor BI (SR-BI) facilitates hepatic very low density lipoprotein (VLDL) production in mice. J. Lipid Res. 51 : 544-553.
25. Maugeais, C., W. Annema, D. Blum, J-L. Mary, and U. J. Tietge. 2013. rHDL administration increases reverse cholesterol transport in mice, but is not additive on top of ezetimibe or cholestyramine treatment. Atherosclerosis. 229 : 94-101.
26. Briand, F., S. U. Naik, I. Fuki, J. S. Millar, C. Macphee, M. Walker, J. Billheimer, G. Rothblat, and D. J. Rader. 2009. Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Clin. Transl. Sci. 2 : 127-133.
27. Sehayek, E., and S. L. Hazen. 2008. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler. Thromb. Vasc. Biol. 28 : 1296-1297.
28. Khatun, I., S. Zeissig, J. Iqbal, M. Wang, D. Curiel, G. S. Shelness, R. S. Blumberg, and M. M. Hussain. 2012. Phospholipid transfer activity of microsomal triglyceride transfer protein produces apolipoprotein B and reduces hepatosteatosis while maintaining low plasma lipids in mice. Hepatology. 55 : 1356-1368.
29. Dikkers, A., J. F. de Boer, W. Annema, A. K. Groen, and U. J. Tietge. 2013. Scavenger receptor BI and ABCG5/G8 differentially impact biliary sterol secretion and reverse cholesterol transport in mice. Hepatology. 58 : 293-303.
30. Wiersma, H., A. Gatti, N. Nijstad, R. P. Oude Elferink, F. Kuipers, and U. J. Tietge. 2009. Scavenger receptor class B type I mediates biliary cholesterol secretion independent of ATP-binding cassette transporter g5/g8 in mice. Hepatology. 50 : 1263-1272.
31. van der Veen, J. N., T. H. van Dijk, C. L. Vrins, H. van Meer, R. Havinga, K. Bijsterveld, U. J. Tietge, A. K. Groen, and F. Kuipers. 2009. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J. Biol. Chem. 284 : 19211-19219.
32. de Boer, J. F., W. Annema, M. Schreurs, J. N. van der Veen, M. van der Giet, N. Nijstad, F. Kuipers, and U. J. Tietge. 2012. Type I diabetes mellitus decreases in vivo macrophage-to-feces reverse cholesterol transport despite increased biliary sterol secretion in mice. J. Lipid Res. 53 : 348-357.
33. Iqbal, J., X. Li, B. H. Chang, L. Chan, G. J. Schwartz, S. C. Chua, Jr., and M. M. Hussain. 2010. An intrinsic gut leptin-melanocortin pathway modulates intestinal microsomal triglyceride transfer protein and lipid absorption. J. Lipid Res. 51 : 1929-1942.
34. Chan, D. C., P. H. Barrett, and G. F. Watts. 2006. Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr. Opin. Lipidol. 17 : 28-36.
35. Visser, M. E., J. L. Witztum, E. S. Stroes, and J. J. Kastelein. 2012. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur. Heart J. 33 : 1451-1458.
36. Duffy, D., and D. J. Rader. 2009. Update on strategies to increase HDL quantity and function. Nat. Rev. Cardiol. 6 : 455-463.
37. Fisher, E. A., J. E. Feig, B. Hewing, S. L. Hazen, and J. D. Smith. 2012. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 32 : 2813-2820.
38. Rosenson, R. S., H. B. Brewer, Jr., W. S. Davidson, Z. A. Fayad, V. Fuster, J. Goldstein, M. Hellerstein, X. C. Jiang, M. C. Phillips, D. J. Rader, et al. 2012. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 125 : 1905-1919.
39. Nijstad, N., T. Gautier, F. Briand, D. J. Rader, and U. J. Tietge. 2011. Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice. Gastroenterology. 140 : 1043-1051.
40. Temel, R. E., and J. M. Brown. 2012. Biliary and nonbiliary contributions to reverse cholesterol transport. Curr. Opin. Lipidol. 23 : 85-90.
41. van der Velde, A. E., C. L. Vrins, K. van den Oever, C. Kunne, R. P. Oude Elferink, F. Kuipers, and A. K. Groen. 2007. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology. 133 : 967-975.
42. Tietge, U. J., and A. K. Groen. 2013. Role the TICE?: advancing the concept of transintestinal cholesterol excretion. Arterioscler. Thromb. Vasc. Biol. 33 : 1452-1453.
43. Vrins, C. L., R. Ottenhoff, K. van den Oever, D. R. de Waart, J. K. Kruyt, Y. Zhao, T. J. van Berkel, L. M. Havekes, J. M. Aerts, M. van Eck, et al. 2012. Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein. J. Lipid Res. 53 : 2017-2023.
44. Le May, C., J. M. Berger, A. Lespine, B. Pillot, X. Prieur, E. Letessier, M. M. Hussain, X. Collet, B. Cariou, and P. Costet. 2013. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler. Thromb. Vasc. Biol. 33 : 1484-1493.
45. Temel, R. E., J. K. Sawyer, L. Yu, C. Lord, C. Degirolamo, A. McDaniel, S. Marshall, N. Wang, R. Shah, L. L. Rudel, et al. 2010. Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Cell Metab. 12 : 96-102.
46. Xie, P., L. Jia, Y. Ma, J. Ou, H. Miao, N. Wang, F. Guo, A. Yazdanyar, X. C. Jiang, and L. Yu. 2013. Ezetimibe inhibits hepatic Niemann-Pick C1-like 1 to facilitate macrophage reverse cholesterol transport in mice. Arterioscler. Thromb. Vasc. Biol. 33 : 920-925.